IP Library › Patent Application 12820614
Patent Application
App. No. 12/820,614

ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/820,614
Abstract

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Claims (13)

1 - 61 . (canceled)

62 . A stent, comprising a generally tubular structure, the surface of which is coated with a composition comprising:

(a) an anti-angiogenic factor; and

(b) a polymeric carrier.

63 . The stent of claim 62 , wherein said anti-angiogenic factor is Anti-Invasive Factor.

64 . The stent of claim 62 , wherein said anti-angiogenic factor is retinoic acid and derivatives thereof.

65 . The stent of claim 62 , wherein said anti-angiogenic factor is selected from the group consisting of Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1 and Plasminogen Activator Inhibitor-2.

66 . The stent of claim 62 , wherein said anti-angiogenic factor is taxol.

67 . The stent of claim 62 , wherein said composition is formed into microspheres having an average size of between 0.5 to 200 um.

68 . The stent of claim 62 , wherein said polymeric carrier is poly(lactic-co-glycolic acid).

69 . The stent of claim 62 , wherein said polymeric carrier is polycaprolactone.

70 . The stent of claim 62 , wherein said polymeric carrier is polylactic acid.

71 . The composition of claim 62 , wherein said polymeric carrier is a copolymer of polylactic acid and polycaprolactone.

Assignments (5)
RELEASE OF SECURITY INTEREST : RECORDED AT REEL/FRAME - 049288/0184 Recorded Jan 29, 2021
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: ANGIOTECH PHARMACEUTICALS, INC.
Reel/Frame 055171/0634 →
SECURITY INTEREST Recorded May 26, 2019
From: ANGIOTECH PHARMACEUTICALS, INC.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 049288/0184 →
RELEASE OF SECURITY INTEREST Recorded Apr 12, 2013
From: WELLS FARGO CAPITAL FINANCE, LLC
To: ANGIOTECH PHARMACEUTICALS, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; ANGIOTECH INTERNATIONAL HOLDINGS CORP.
Reel/Frame 030211/0479 →
PATENT SECURITY AGREEMENT Recorded May 13, 2011
From: ANGIOTECH PHARMACEUTICALS, INC.; AFMEDICA, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH DELAWARE, INC.; ANGIOTECH FLORIDA HOLDINGS, INC.; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; NEUCOLL INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; 0741693 BRITISH COLUMBIA LTD.; ANGIOTECH INTERNATIONAL HOLDINGS, CORP.
To: WELLS FARGO CAPITAL FINANCE, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 026275/0507 →
PATENT SECURITY AGREEMENT Recorded Aug 19, 2010
From: ANGIOTECH PHARMACEUTICALS, INC.; AFMEDIA, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH CAPITAL, LLC; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; CRIMSON CARDINAL CAPITAL, LLC; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; NEUCOLL, INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALITIES CORPORATION; 0741693 B.C. LTD.; 3091796 NOVA SCOTIA COMPANY; ANGIOTECH INTERNATIONAL HOLDINGS, CORP.; ANGIOTECH INVESTMENT PARTNERSHIP
To: WELLS FARGO FOOTHILL, LLC, AS AGENT
Reel/Frame 024861/0219 →